Therapeutic implications of Babesia canis infection in dogs.
The therapeutic regime used in the treatment of dogs with Babesia canis infection differed between dogs with mild (uncomplicated) and severe (complicated) disease. In addition to the treatment given to dogs with mild disease, the dogs with severe disease received intravenous fluids, heparin and blood transfusion together with other supportive measures. Mortalities occurred only in the group with severe disease and were attributed to disseminated intravascular coagulation.
D000208:Acute Disease; D000578:Amidines / Q000627:therapeutic use*; D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D001404:Babesiosis / Q000188:drug therapy / Q000628:therapy*; D001550:Benzamidines / Q000627:therapeutic use*; D004133:Diminazene / Q000031:analogs & derivatives / Q000627:therapeutic use*; D004211:Disseminated Intravascular Coagulation / Q000150:complications; D004283:Dog Diseases / Q000628:therapy*; D004285:Dogs; D004359:Drug Therapy, Combination; D007263:Infusions, Parenteral; D010647:Phenyl Ethers / Q000627:therapeutic use*; D014343:Trypan Blue / Q000627:therapeutic use*
D000578:Amidines; D000981:Antiprotozoal Agents; D001550:Benzamidines; D010647:Phenyl Ethers; C001787:phenamidine; D014343:Trypan Blue; C003915:diminazene aceturate; D004133:Diminazene